Burnout, dissatisfaction with EHRs increase physician turnover

According to a study published in Mayo Clinic Proceedings, physician burnout, dissatisfaction with electronic health records (EHRs) and work-life imbalance are main reasons why physicians leave current positions.

The study surveyed 6,880 physicians from August 28 to October 6, 2014 to assess information on the likelihood of reducing clinical hours in the next year or leaving their current practice within the next two years. The factors of burnout, satisfaction with EHRs and work-life balance were examined in their effect to the career plans of physicians.

Of the 6,695 physicians that were in clinical practice at the time of the survey, 19.8 percent stated it was likely they would reduce clinical work hours in the next year and 26.6 percent stated it was likely they would leave their current position within the next two years.

“Nearly one in five U.S. physicians intends to reduce clinical work hours in the next year, and roughly one in 50 intends to leave medicine altogether in the next two years to pursue a different career,” concluded first author Christine A. Sinsky, MD, vice president of professional satisfaction at the American Medical Association, and colleagues. “If physicians follow through on these intentions, it could profoundly worsen the projected shortage of US physicians.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.